On March 1, 2019, Segulah IV L.P. and minority shareholders signed an agreement to divest 100% of CCS Healthcare Holding AB to KiiltoClean Group. KiiltoClean Group is a part of Kiilto, a family-owned Finnish company that develops, manufactures and markets chemical industry solutions and operates in four business areas: construction, industrial bonding and hygiene solutions, professional cleanliness and hygiene and consumer products. The transaction was simultaneously carried through.

CCS Healthcare provides hygiene and safety products to the professional business-to-business markets and holds the leading position within hand hygiene and surface disinfection products in the Nordic region. Additionally, the Company holds a strong position within portable eyewash products in Denmark and Germany.

CCS Healthcare was acquired by Segulah IV in May 2011. During Segulah IV’s ownership, CCS Healthcare has completed four add-on acquisitions, mainly within the hygiene product segment. In March 2016, CCS Healthcare divested its pharma portfolio and Clinomyn brand to Trimb Healthcare. The Consumer Skincare business unit was divested through two separate transactions in January 2019. The skincare brand portfolio was acquired by Trimb Healthcare and the factory and contract manufacturing activities in Sweden were acquired by Svenska Krämfabriken. Pro forma for the Consumer Skincare divestment, CCS Healthcare generated revenues of ca. MSEK 440 in 2018.

“CCS Healthcare has in recent years significantly transformed its operations and showed good profitable growth. Following the successful divestment of the Consumer Skincare business unit, the industrial merit of combining CCS Healthcare with Kiilto is evident, creating a Nordic powerhouse positioned for future growth”, says Dario Aganovic, CEO of CCS Healthcare.

”We are very pleased with how CCS Healthcare has performed over the past years under the leadership of the current management team. We are convinced that Kiilto as a new owner will be able to further develop CCS Healthcare’s strong position across key Nordic and European markets”, says Sebastian Ehrnrooth, Chairman of Segulah Advisor AB.

For further information please contact:

Dario Aganovic, CEO, CCS Healthcare, +46 72 555 11 01

Sebastian Ehrnrooth, Chairman, Segulah Advisor AB, +46 73 360 42 05

Johan Möllerström, Director, Segulah Advisor AB, +46 72 543 79 11

Blackstone Life Sciences provides $250M Financing

Cambridge, Massachusetts, February 27, 2019 – Blackstone Life Sciences today announced the launch of Anthos Therapeutics Inc. (“Anthos”), a new biopharmaceutical company focused on advancing next-generation targeted therapies for high-risk cardiovascular patients.

As part of this launch, Novartis has licensed to Anthos MAA868, an antibody directed at Factor XI and XIa, key components of the intrinsic coagulation pathway. A large unmet medical need exists for next-generation anti-thrombotic therapies in patients currently underserved by conventional anti-coagulant therapies. As a promising anti-thrombotic modulating genetically and pharmacologically validated components of the intrinsic pathway, MAA868 has the potential to prevent a variety of cardiovascular disorders with minimal or no bleeding risk within a new long-acting treatment paradigm, which would provide major advantages over the conventional standards of care.

Funds managed by Blackstone Life Sciences, a private investment platform with capabilities to invest across the lifecycle of companies and products within the key life sciences sectors, provided $250M for Anthos and will control the development of the products.  Novartis will retain a minority equity interest in Anthos.

According to the American Heart Association, thrombotic disorders cause nearly 500,000 deaths each year. Thrombotic disorders can affect arteries or veins, manifesting as ischemic heart disease, ischemic stroke, peripheral artery disease, venous thromboembolism, and many debilitating orphan diseases. Atrial fibrillation, the most common type of heart arrhythmia, is a major risk factor for ischemic stroke and systemic arterial thromboembolism.

“The need for new medicines to treat cardiovascular diseases is clear, and this agreement is part of our strategy to work with innovators outside our walls to advance medicines that have the potential to have a positive impact for patients,” said Jay Bradner, MD, President of the Novartis Institutes for BioMedical Research. “Blackstone Life Sciences has the necessary experience and has assembled a first-class team at Anthos to drive the further development of MAA868.”

“Blackstone Life Sciences is focused on bringing important medicines and healthcare technologies to market, often working in partnership with major biopharmaceutical companies to provide them with access to capital, scientific expertise and hands-on operational leadership,” said Nick Galakatos, Ph.D., Head of Blackstone Life Sciences and Chairman of Anthos.  “We are excited to collaborate with Novartis to create Anthos, with the goal of delivering important therapies for the high-risk cardiovascular patients who need them.”

Founding members of Anthos’ Board of Directors include Blackstone Managing Director Paris Panayiotopoulos, former CEO of Ariad Pharmaceuticals, and Blackstone Principal Ari Brettman, MD. Jonathan Freeman, MBA, Ph.D., Blackstone Senior Advisor and Anthos co-founder, joins as Chief Operating Officer.

Shaun Coughlin, MD, Ph.D., Novartis’ Global Head of Cardiovascular and Metabolism joins as an Observer to Anthos’ Board. Craig Basson, MD, Ph.D., Novartis’ Head of Cardiovascular and Metabolism Translational Medicine joins Anthos’ Scientific Advisory Board.

John Glasspool, a former leader of Novartis’ cardiovascular franchise with 30 years of experience in the biopharmaceutical industry, joins Anthos as CEO. Mr. Glasspool served as Global Head of Novartis’ Cardiovascular and Metabolic Diseases franchise from 2004-2008 and more recently served as Head of Corporate Strategy and a member of the Executive Team at Baxalta that led its acquisition by Shire.

“I am excited to be leading Anthos upon its formation by Blackstone Life Sciences and Novartis. Anthos is well-positioned to leverage contributions from Blackstone and Novartis to deliver life-saving therapies to patients with cardiovascular disease. We are building a leading cardiovascular company, laser focused on genetically and pharmacologically validated targets.” said Mr. Glasspool.

Anthos Therapeutics is based in Cambridge, Massachusetts.

About Anthos Therapeutics
Anthos Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated therapies for high-risk cardiovascular patient populations. Anthos’ most advanced program is MAA868, an anti- Factor XI / XIa monoclonal antibody, which represents a promising next generation anti-thrombotic investigational therapy with the potential to prevent multiple thrombotic diseases with minimal or no bleeding risk. Anthos is located in Cambridge, Massachusetts.

About Blackstone Life Sciences
Blackstone Life Sciences is a private investment platform with capabilities to invest across the life-cycle of companies and products within the key life science sectors.  By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines that improve patients’ lives. In launching this new platform, Blackstone acquired Clarus, a leading global life-sciences firm.

Contacts
Blackstone
Jennifer Friedman
+1 (212) 583-5122
Jennifer.Friedman@blackstone.com

Novartis
Eric Althoff
+1 (646) 438-4335
Eric.Althoff@novartis.com

Calypso Biotech, an emerging leader in the development of therapeutic antibodies for autoimmune diseases, announces today the closing of a €20M Series A financing co-led by Gilde Healthcare and Inkef Capital. They are joined by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the company’s founding investor M Ventures. Further, Calypso Biotech has become Resident Company at Johnson & Johnson Innovation JLABS at Beerse in Belgium (JLABS@BE). Arthur Franken from Gilde Healthcare will join Fiona MacLaughlin (Inkef Capital), Jeanne Bolger (JJDC) and Jasper Bos (M Ventures) on the Board of Directors.

The proceeds from this financing round will support the development of Calypso Biotech’s best-in class anti-Interleukin-15 (IL-15) antibody CALY-002 up to First-in-Patient studies in several autoimmune indications. IL-15 is an immune checkpoint cytokine that controls inflammation as well as multiple tissue-resident immune cells and recently attracted much attention in the immune-oncology space. Especially, IL-15 is being recognized as a key factor in the survival of tissue resident memory T cells, a population of immune cells involved in disease maintenance and recurrence.  Calypso Biotech scientists believe that targeting tissue resident memory T cells offers significant advantages over traditional cytokine interventional approaches and could provide for unprecedented disease-modifying effects.

Calypso Biotech has chosen to develop CALY-002 in Eosinophilic Esophagitis (EoE) as well as in other undisclosed auto-immune indications. EoE is a severe and debilitating immune-related chronic disease of the esophagus that is the second leading cause of dysphagia (difficulty in swallowing) in adults. EoE has emerged as a frequent and significant cause of upper gastrointestinal morbidity particularly associated with important quality of life impairment and significant financial healthcare burden. CALY-002 has secured Orphan Drug Designation status from the European Medicines and Food & Drug Administration agencies for EoE.

“We believe the unique immunological insight and understanding  for the role of IL15 in disease brought by founders Alain Vicari and Yolande Chvatchko is now ready for translation into a therapy for patients with EoE, for whom limited therapies are available today, as well as in several large auto-immune indications” said Fiona MacLaughlin, Inkef Capital.

Calypso Biotech is also announcing major strengthening of its team. Bernard Coulie, current president and CEO of Pliant Therapeutics, will be appointed as independent Chairman of the Board. Together with Alexandre LeBeaut, Executive Vice-President and CSO of Ipsen and current independent Director of Calypso Biotech, they will contribute to develop its strategic vision and corporate success. Prof. Bart Lambrecht, from the VIB-UGent Center for Inflammation Research (Belgium), a leading translational immunology expert, will join Calypso Biotech Scientific Advisory Board. Dr. Josephin-Beate Holz (ex Ablynx NV), Dr Greg Elson (ex Glenmark, Novimmune), Dr Susana Salgado (ex Novimmune), and Duc Tran (ex Prexton Therepeutics, Preglem, Pfizer) will join as medical, manufacturing, non-clinical development and strategic planning advisors, respectively.

“We appreciate the confidence placed in our team by a strong and well-balanced investor syndicate” said Alain Vicari, CEO and co-Founder of Calypso Biotech. “With the proceeds of the Series A and our newly recruited team of seasoned experts, we are now well positioned to advance CALY-002 towards value-creating near-term milestones”.

–

 About Calypso Biotech BV

Calypso Biotech BV is a private biotechnology company focused on the research and development of novel biologics to address unmet medical need in immunological diseases, especially gastrointestinal indications. Calypso Biotech was established in 2013 as a spin-off by the healthcare business of Merck founded by Alain Vicari, Yolande Chvatchko and M Ventures, and is headquartered in Amsterdam, The Netherlands. Calypso is led by a team with strong experience and track record in translational immunology and the development of biologics, supported by an advisory board of clinical experts. For more information www.calypsobiotech.com

About INKEF Capital

INKEF Capital is an Amsterdam-based venture capital firm that focuses on long-term collaboration and active support of innovative technology companies. INKEF Capital was founded in 2010 by Dutch pension fund ABP and with €500 million under management is one of the largest venture capital funds in the Netherlands. INKEF focuses on investment opportunities in Healthcare, Technology, IT/New Media & FinTech. For more information www.inkefcapital.com

Colisée, a leading player in the elderly care segment in France, Italy and Spain, has signed an agreement to acquire Armonea Group NV, a leading independent senior care organisation in Belgium also active in Spain and Germany. Colisée is supported by the IK VIII Fund and its advisor IK Investment Partners. Financial terms of the transaction are not disclosed and completion of the transaction is subject to regulatory approvals.

Founded in 2008 from the merger of Restel Residences and Group Van den Brande, Armonea is the leading senior care organisation in Belgium, Spain and Germany with more than 17,000 beds under management. The Company manages nursing homes, service flats & residencies. Owned by Verlinvest and Group Van den Brande, Armonea is headquartered in Belgium and employs c. 6,500 FTEs.

The acquisition of Armonea is at the core of Colisée’s strategy to build a European leader in the elderly care segment.

The combination of Armonea and Colisée is based on a complementary geographic profile as well as shared values and vision that will enable synergies at a group level. The combined Group will become the fourth largest European player in the elderly care segment with c. €1bn of revenues.

”This is the combination of two recognised players in their core geographies, with a clear alignment in terms of culture and shared values. Both strive to offer the highest quality of care to their residents. We are very pleased to welcome Armonea’s management team and employees in a combined group totalling c.270 facilities and more than 26,800 residents in five major European countries,” said Christine Jeandel, CEO of Colisée.

”We are delighted and very proud to support Colisée in building the fourth largest European player, thus actively participating in the reshaping of a consolidating industry. We look forward to partnering with an enlarged, experienced and talented management team led by Christine Jeandel,” added Dan Soudry, Managing Partner at IK.

The Group will refinance its existing debt with the support of Barclays, Natixis, SG and CIC. The transaction is subject to regulatory approvals.

Parties involved 
Colisée: Christine Jeandel, Damien Delacourt, Alexis Jungels, Brigitte Siad
IK Investment Partners: Dan Soudry, Rémi Buttiaux, Diki Korniloff, Guillaume Veber, Vincent Valkiers
Buy-side M&A advisors: Lazard (Francois Guichot-Perere, Emmanuel Plantin), Natixis Partners (Ludovic Tron), Case (Damien Segond, William Gobbi)
Buy-side Strategic DD: LEK (Serge Hovsepian, Arnaud Sergent)
Buy-side Financial DD: 8A (Pascal Raidron, Katia Wagner)
Buy-side Legal advisor: White & Case (Thierry Bosly, Muriel Alhadeff, Raphael Richard)
Financing banks: Natixis (Arnaud Brogi), Barclays (Thibery Gleizes), CIC (Brice Bourrely), SG (Patrick Sandray)
Legal advisors financing banks: Latham & Watkins (Xavier Farde)
Sell-side M&A advisors: Rothschild (Franck Demeoen, Jean-Francois Limpens), PJT (Alberto Fernandez, Kiara Mitchinson)

For further questions, please contact: 

Colisée
Marie-Gabrielle de Marchis
Phone: +33 6 69 40 32 17
mg.demarchis@nouvellesaison.com

Armonea
Koen Peeters
Phone: +33 1 70 38 25 54
koen.peeters@armonea.be

IK Investment Partners
Dan Soudry, Partner
Phone: +33 1 44 43 06 60

Mikaela Murekian
Director Communications & ESG
Phone: +44 77 87 573 566
mikaela.murekian@ikinvest.com

About Colisée
Colisée is a key player in the global health care and old-age dependency sector, and has developed a real expertise in elderly people care and well-being. Its network includes 119 facilities in France, Italy and Spain and home-based services agencies in France. In those two business segments, Colisée employs more than 8,000 people. For more information, please visit www.groupecolisee.com

About Armonea
Armonea is the largest independent senior care organisation in Belgium. Every day our 6,500 employees help more than 9,000 seniors enjoy their age in the way that suits them best. In its (almost) 40 years of existence Armonea gained a great deal of expertise in dementia, including with a specialised residential care center in Uccle. Through our dementia knowledge center Anahata, we share this knowledge and experience with our 74 residential care centers in Flanders, Brussels and Wallonia. Armonea also provides stays in residences or assistance homes. Armonea is also active in Spain and Germany. More information about Armonea and our residential care centers on www.armonea.be

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €9.5 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

• Merger creates company with combined revenues of more than EUR 1.7bn
• Transaction expected to close in early March 2019
• Truly global footprint through comprehensive sales and distribution platform

Singapore and Lynge, Denmark – February 14, 2019: The European Commission has approved, under the EU Merger Regulation, the merger between Sivantos Pte. Ltd. (“Sivantos”), owned by EQT funds, and Widex A/S (“Widex”), owned by T&W Medical A/S. Sivantos offers a diverse portfolio of technologically advanced hearing aid products across brands like Signia, Audio Service, Rexton and others. Widex’ portfolio of products includes a range of sophisticated hearing aid technology with a focus on the high-end segment.

The Commission concluded the merger would raise no competition concerns. The merger has already been approved in all other relevant jurisdictions.

“Our goal at Widex has always been to develop the best possible hearing aids to improve the life of those with hearing needs. The merger with Sivantos brings us one step closer to that goal by building a company with one of the strongest research and development resources in the business and the sales channels to ensure our innovative products reach as many people as possible,” said Jan Tøpholm, Chairman of Widex A/S.

“The merger between Widex and Sivantos is a transformative combination and unique opportunity to drive innovation through one of the most dynamic R&D teams in the industry to benefit the more than 700 million people with hearing needs,” said Marcus Brennecke, Global Co-Head of EQT Private Equity.

The newly created company will be a global leader with a presence in more than 125 markets, combined revenues of more than EUR 1.7 billion and more than 10,000 employees worldwide. All Widex and Sivantos brands will continue to operate with separate sales forces and organizations following the combination.

The transaction remains subject to final and customary closing conditions. The parties expect the transaction to close in early March 2019.

This press release is translated into multiple languages for information purposes. In case of a discrepancy, the English version shall prevail. To read this press release in Danish, follow this link.

Contacts
Widex | Andrew Arnold (Corporate Communications): +45 25 65 75 47
Sivantos | Gert van Santen (Corporate Communications): +49 152 028 743 20
EQT | Press office: press@eqtpartners.com, +46 8 506 55 334

About Sivantos Group
The business operations of the former Siemens AG hearing aid division have been combined into the Sivantos Group since early 2015. Sivantos can look back on 140 years of German engineering and countless global innovations. Today Sivantos is one of the leading hearing aid manufacturers worldwide, with brands like Signia, Audio Service, Rexton and others. With its around 6,000 employees, the group recorded revenues of 1100 million euros in the fiscal year 2017/2018 and an adj. EBITDA of 262 million euros. Sivantos’ international sales organization supplies hearing care specialists and sales partners in more than 120 countries. Particularly high value is placed on product development. The owners of Sivantos are the anchor investors EQT along with the Strüngmann family as a co-investor. Sivantos GmbH is a brand license holder of Siemens AG.

More info: www.sivantos.com

About Widex
With more than 60 years’ experience developing state-of-the-art hearing technology, Widex (headquartered in Lynge, Denmark) provides hearing solutions that are easy to use, seamlessly integrated in daily life and enable people to hear naturally. One of the world’s leading hearing aid producers, Widex employs around 4,250 people across sales, manufacturing, operations, distribution and R&D in 38 countries, and its products are sold in 105 countries. The current strategy, introduced in 2018, aims at doubling the business in five years. Widex is owned by the Tøpholm and Westermann families, descendants of the founders.

More info: www.widex.com

About EQT
EQT is a leading investment firm with approximately EUR 50 billion in raised capital across 28 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtpartners.com

Andera Partners and a syndicate of international investors finance a new CNS-focused European biopharma company Arvelle Therapeutics

Andera Partners participated in the Series A financing of Arvelle Therapeutics, a newly-formed company that acquired exclusive European rights to Cenobamate, a highly differentiated anti-epileptic compound. The new CNS-focused company, received one of the largest initial financing commitments for a European-focused biopharmaceutical company from a global syndicate which, aside from Andera Partners, includes NovaQuest Capital Management, Life Sciences Partners, BRV Capital Management and H.I.G. BioHealth Partners.

Arvelle Therapeutics acquired the drug from SK Biopharmaceuticals for an upfront payment of $100 million and future potential milestones of up to $430 million. The company intends to file a Marketing Authorization Application (MAA) for cenobamate for partial-onset seizures in adult patients.

Oliver Litzka, Partner at Andera Partners, will join the board of Arvelle alongside other syndicate members.

The press release issued by the company and SK Biopharmaceuticals is available here.

• EQT brings in blue chip investors in a minority stake sale in IVC at an enterprise value of approximately EUR 3.0 billion
• EQT remains the largest shareholder and continues to invest in IVC with around 20% of the capital held by institutional minority investors
• Kate Swann, CEO of SSP Group plc and former CEO of WHSmith PLC, appointed as new Chairman of IVC effective today, having already served as a member of the board of IVC

EQT today announced that the EQT VI and VII funds (jointly “EQT”) bring in a group of partners through a minority stake sale in IVC Group (“IVC” or “the Company”) to support accelerated growth in its next development phase. The transaction values IVC at an enterprise value of approximately EUR 3.0 billion. Around 20% of the capital will be held by institutional minority investors.

Headquartered in Bristol, UK, IVC is a leading veterinary services provider with a network of more than 1,100 clinics and hospitals and approximately 16,000 employees across Europe. Founded in 2011, IVC operates a decentralized model promoting innovation and clinical freedom balanced with integrated support functions such as procurement, veterinary advisors and clinical boards.

IVC was acquired by EQT in December 2016, and in May 2017 the Company was merged with Evidensia, a Swedish veterinary group (also owned by EQT), which at the time operated a network of 180 clinics and hospitals across the Nordics and Central Europe. Since then, IVC has transformed into the leading European veterinary services provider through accelerated organic growth and a large number of strategic add-on acquisitions.

In connection with the minority stake sale, IVC successfully refinanced the business with a first lien facility raised alongside a second lien facility in total of approximately EUR 1.2 billion in addition to a EUR 230 million RCF. The refinancing is designed to allow IVC to continue to drive further consolidation of the European veterinary market.

Per Franzén, Partner at EQT Partners and Investment Advisor to EQT VI and EQT VII, comments: “EQT is pleased to welcome the new investors and delighted about the strong support from IVC’s financing providers. The new ownership structure, combined with the successful refinancing, constitute a solid foundation for continuing IVC’s journey towards becoming Europe’s leading veterinary services group. We are also excited to appoint Kate Swann as new Chairman of the board. She brings an impressive track record of long-term sustainable shareholder value creation from leading both SSP and WHSmith and will be ideally suited to support the management team in the future-proofing of IVC.”

David Hillier, CEO of IVC, adds: “IVC has grown immensely during EQT’s ownership and we see attractive opportunities to continue expanding our business across Europe, both organically through increased market penetration and via continued acquisitive growth and consolidation of the highly fragmented veterinary market. We welcome our new partners and look forward to their support in realizing our goal. We are also happy to see Kate Swann appointed as Chairman of the board, having already served as a member of the board.”

Kate Swann, Chairman of IVC, concludes: “I look forward to supporting David, his management team and EQT on the mission to create Europe’s leading veterinary services provider”.

The transaction and refinancing completed on February 13, 2019.

Contacts
Per Franzén, Partner at EQT Partners and Investment Advisor to EQT VI and EQT VII, +46 8 506 554 50
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT
EQT is a leading alternative investments firm with more than EUR 50 billion in raised capital across 28 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. 

More info: www.eqtpartners.com

About Independent Vetcare
IVC is the largest and most diversified vet services platform in Europe with more than 1,100 clinics and hospitals across 10 countries. IVC employs approximately 16,000 FTEs, including over 4,000 veterinarians.

More info: www.ivc.group

MINNEAPOLIS, Feb. 11, 2019 /PRNewswire/ — Nuvaira, a developer of novel therapeutic medical devices to treat obstructive lung diseases, announced today it has closed a $79 million equity financing led by U.S. Venture Partners, with Endeavour Vision, Qiming Venture Partners, Lightstone Ventures and Richard King Mellon Foundation joining the round, along with all of Nuvaira’s existing investors: Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings, and Windham Venture Partners.

“We are thrilled to have such a strong consortium of top-tier investors in this financing, as a clear vote of confidence in our work and the performance of our novel catheter-based system in our Phase 2b randomized, sham-controlled trial in patients with chronic obstructive pulmonary disease (COPD) patients,” said Dennis Wahr, M.D., Chief Executive Officer of Nuvaira. “These funds will be used to support the pivotal AIRFLOW-3 clinical trial for FDA approval, and to implement a targeted clinical development strategy in key European markets.”

Nuvaira’s Lung Denervation System addresses airway hyper-responsiveness, a pathophysiologic underpinning of both COPD and asthma in a procedure called Targeted Lung Denervation (TLD). Nuvaira’s proprietary technology has demonstrated safety and feasibility in three clinical studies: IPS-I/II, AIRFLOW-1, and, most recently, the AIRFLOW-2 sham controlled randomized clinical trial, which was presented at the European Respiratory Society conference in September 2018.

Nuvaira is the first interventional pulmonary company to pursue and report one-year randomized, double-blinded and sham-controlled clinical evidence in COPD patients from a Phase 2b trial. “The rigor of the AIRFLOW-2 trial has set a high standard for the field,” said Dr. Frank Sciurba, Professor of Medicine at UPMC in Pittsburgh, PA and U.S. principal investigator of Nuvaira’s AIRFLOW-3 trial. “We are encouraged by the results of the AIRFLOW-2 trial, and we see TLD potentially filling an unmet need for our COPD patients who continue to have exacerbations while on maximal guideline-based pharmacologic therapy.”

The company also announced that Lisa Rogan has joined its executive team as senior vice president of market development, bringing with her over 20 years of medical device industry expertise in commercializing disruptive diagnostic and therapeutic technologies, including ten years of experience with interventional pulmonary devices targeting treatment of severe COPD.

“We are extremely excited to have Lisa Rogan join our executive team at Nuvaira,” said Dr. Wahr. “She has a deep understanding and knowledge of the pulmonary field having spent the past decade in it, and she brings with her great business acumen and expertise in accessing new markets.”

About Nuvaira
Nuvaira is a privately held company headquartered in Minneapolis, Minn. The company has developed the Nuvaira Lung Denervation System to address chronic lung diseases by treating the overactive airway nerves with Targeted Lung Denervation (TLD). The Nuvaira Lung Denervation System is CE Mark approved. The Nuvaira Lung Denervation System is under clinical investigation and is not commercially available in the USA. Nuvaira and dNerva are registered trademarks of Nuvaira, Inc. Please visit us at www.Nuvaira.com.